Boston Sci ($BSX) agrees to pay up to $450M for Sadra Medical

Boston Scientific ($BSX) has signed an agreement to buy Sadra Medical, a development-stage company in Los Gatos, California, for up to $450 million. The agreement calls for an upfront payment of $225 million plus additional potential payments of up to $225 million upon achievement of specified regulatory and revenue-based milestones through 2016. The company has been a strategic investor in Sadra since 2006. According to a Boston Sci release, Sadra is developing the first fully repositionable device for percutaneous aortic valve replacement to treat patients with severe aortic stenosis. Boston Scientific release

Suggested Articles

Takeda tapped Roche’s Foundation Medicine to develop tissue- and blood-based companion diagnostic tests for its portfolio of lung cancer therapies.

Cellex has announced plans to develop a rapid coronavirus test that people can fully perform at home, from sample collection to result, using an app.

More than 20 states either don’t release or have incomplete data on the rapid antigen tests now considered key to containing the coronavirus.